Expectations in children with glomerular diseases from SGLT2 inhibitors
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Expectations in children with glomerular diseases from SGLT2 inhibitors
Authors
Keywords
-
Journal
PEDIATRIC NEPHROLOGY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-03-14
DOI
10.1007/s00467-022-05504-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A kidney perspective on the mechanism of action of sodium glucose co-transporter 2 inhibitors
- (2021) Taha Sen et al. Cell Metabolism
- A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy
- (2021) David C. Wheeler et al. KIDNEY INTERNATIONAL
- Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial
- (2021) Brendon L Neuen et al. EUROPEAN HEART JOURNAL
- Empagliflozin in Heart Failure with a Preserved Ejection Fraction
- (2021) Stefan D. Anker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Long-Term Complications in Youth-Onset Type 2 Diabetes
- (2021) NEW ENGLAND JOURNAL OF MEDICINE
- Pediatric Onco-Nephrology: Time to Spread the Word-Part II: Long-Term Kidney Outcomes in Survivors of Childhood Malignancy and Malignancy after Kidney Transplant
- (2021) Arwa Nada et al. PEDIATRIC NEPHROLOGY
- KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
- (2021) Brad H. Rovin et al. KIDNEY INTERNATIONAL
- Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial
- (2021) Hiddo J L Heerspink et al. Lancet Diabetes & Endocrinology
- Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial
- (2021) Niels Jongs et al. Lancet Diabetes & Endocrinology
- IPNA clinical practice recommendations for the diagnosis and management of children with steroid-resistant nephrotic syndrome
- (2020) Agnes Trautmann et al. PEDIATRIC NEPHROLOGY
- Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial
- (2020) David Z I Cherney et al. Lancet Diabetes & Endocrinology
- Podocytopathies
- (2020) Jeffrey B. Kopp et al. Nature Reviews Disease Primers
- Children with CKD Are Not Little Adults with CKD
- (2020) Alexander J. Kula et al. Clinical Journal of the American Society of Nephrology
- Dapagliflozin Added to Verinurad Plus Febuxostat Further Reduces Serum Uric Acid in Hyperuricemia: The QUARTZ Study
- (2020) Austin G Stack et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Early Change in Albuminuria with Canagliflozin Predicts Kidney and Cardiovascular Outcomes: A PostHoc Analysis from the CREDENCE Trial
- (2020) Megumi Oshima et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics
- (2020) David C Wheeler et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Dapagliflozin in Patients with Chronic Kidney Disease
- (2020) Hiddo J.L. Heerspink et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
- (2020) George L. Bakris et al. NEW ENGLAND JOURNAL OF MEDICINE
- Natriuretic Effect of Two Weeks of Dapagliflozin Treatment in Patients With Type 2 Diabetes and Preserved Kidney Function During Standardized Sodium Intake: Results of the DAPASALT Trial
- (2020) Rosalie A. Scholtes et al. DIABETES CARE
- SGLT2 inhibition requires reconsideration of fundamental paradigms in chronic kidney disease, ‘diabetic nephropathy’, IgA nephropathy and podocytopathies with FSGS lesions
- (2020) Hans-Joachim Anders et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis
- (2019) Tadashi Toyama et al. DIABETES OBESITY & METABOLISM
- Effect of SGLT2 inhibitors on body composition, fluid status and renin–angiotensin–aldosterone system in type 2 diabetes: a prospective study using bioimpedance spectroscopy
- (2019) Anja Schork et al. Cardiovascular Diabetology
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evaluation of Glomerular Hemodynamic Function by Empagliflozin in Diabetic Mice Using In Vivo Imaging
- (2019) Kengo Kidokoro et al. CIRCULATION
- Effects of dapagliflozin on urinary metabolites in people with type 2 diabetes
- (2019) Skander Mulder et al. DIABETES OBESITY & METABOLISM
- SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis
- (2019) Brendon L Neuen et al. Lancet Diabetes & Endocrinology
- Dapagliflozin: A Review in Type 1 Diabetes
- (2019) Julia Paik et al. DRUGS
- Reverse Phenotyping after Whole-Exome Sequencing in Steroid-Resistant Nephrotic Syndrome
- (2019) Samuela Landini et al. Clinical Journal of the American Society of Nephrology
- Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial
- (2019) Hiddo J L Heerspink et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- SGLT2 inhibitors as adjunctive therapy for type 1 diabetes: balancing benefits and risks
- (2019) Simeon I Taylor et al. Lancet Diabetes & Endocrinology
- Bardoxolone Methyl Improves Kidney Function in Patients with Chronic Kidney Disease Stage 4 and Type 2 Diabetes: Post-Hoc Analyses from Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes Study
- (2018) Melanie P. Chin et al. AMERICAN JOURNAL OF NEPHROLOGY
- Evolving Epidemiology of Pediatric Glomerular Disease
- (2018) Michelle N. Rheault et al. Clinical Journal of the American Society of Nephrology
- A Disturbing Legacy of Childhood Kidney Disease
- (2018) Julie R. Ingelfinger NEW ENGLAND JOURNAL OF MEDICINE
- Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial
- (2018) Christoph Wanner et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Effect of Oral Methylprednisolone on Clinical Outcomes in Patients With IgA Nephropathy
- (2017) Jicheng Lv et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- A developmental approach to the prevention of hypertension and kidney disease: a report from the Low Birth Weight and Nephron Number Working Group
- (2017) Valerie A Luyckx et al. LANCET
- Effect of Sodium‐Glucose Cotransport‐2 Inhibitors on Blood Pressure in People With Type 2 Diabetes Mellitus: A Systematic Review and Meta‐Analysis of 43 Randomized Control Trials With 22 528 Patients
- (2017) Mohsen Mazidi et al. Journal of the American Heart Association
- Chronic kidney disease
- (2017) Paola Romagnani et al. Nature Reviews Disease Primers
- Prevalence of chronic kidney disease risk factors among low birth weight adolescents
- (2016) Dev Darshan K. Khalsa et al. PEDIATRIC NEPHROLOGY
- Low Birth Weight and Risk of Progression to End Stage Renal Disease in IgA Nephropathy—A Retrospective Registry-Based Cohort Study
- (2016) Paschal Ruggajo et al. PLoS One
- Genome-Wide Association Studies in Nephrology: Using Known Associations for Data Checks
- (2015) Matthias Wuttke et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Obesity, metabolic health, and the risk of end-stage renal disease
- (2015) Bhupesh Panwar et al. KIDNEY INTERNATIONAL
- The ketone metabolite β-hydroxybutyrate blocks NLRP3 inflammasome–mediated inflammatory disease
- (2015) Yun-Hee Youm et al. NATURE MEDICINE
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Intensive Supportive Care plus Immunosuppression in IgA Nephropathy
- (2015) Thomas Rauen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Acetazolamide on Obesity-Induced Glomerular Hyperfiltration: A Randomized Controlled Trial
- (2015) Boris Zingerman et al. PLoS One
- Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus
- (2013) David Z.I. Cherney et al. CIRCULATION
- A Clinical Trial to Maintain Glycemic Control in Youth with Type 2 Diabetes
- (2012) NEW ENGLAND JOURNAL OF MEDICINE
- Avosentan for Overt Diabetic Nephropathy
- (2010) J. F.E. Mann et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial
- (2010) Dick de Zeeuw et al. LANCET
- Avosentan Reduces Albumin Excretion in Diabetics with Macroalbuminuria
- (2009) R. R. Wenzel et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Obesity-induced glomerular hyperfiltration: its involvement in the pathogenesis of tubular sodium reabsorption
- (2008) A. Chagnac et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now